Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-ranging trial of the GRAdHIVNE1 HIV vaccine in adults with and without HIV in Southern Africa
PACTR202504569597313Phase 1Not yet recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Feb 2025
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GRAdHIVNE1 in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Reactogenicity, Unsolicited adverse events and laboratory safety and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
GRAdHIVNE1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202504569597313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504569597313.